Blame Over Fosamax Draws Sharp Debate

Law360, New York (June 14, 2007, 12:00 AM EDT) -- The battle may be shaping up to be one of David and Goliath proportions, but for Ramon Harrison and hundreds of others like him, the chance to take Merck & Co. to task over its osteoporosis drug Fosamax is well worth the risk.

While Merck may already have its hands full trying to fend off thousands of Vioxx suits, another front has opened up in the pharmaceutical giant's product liability war as accusations fly that Fosamax actually leads to jaw deterioration.

Harrison, who took Fosamax for...
To view the full article, register now.